Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URTH: Reduced Intensity Conditioning HCT for Thalassemia
NCT01005576Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2010
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab, fludarabine, melphalan, thiotepa and hydroxyurea in beta thalassemia major, sponsored by Washington University School of Medicine. Primary endpoint: Event-free Survival at 1 year. Started Jan 2010; status: completed.
02
Drugs
alemtuzumabfludarabinemelphalanthiotepahydroxyurea
03
Conditions
beta thalassemia major
Beyond the preview
Go deeper on NCT01005576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01005576.